United Therapeutics Corp (NAS:UTHR)
$ 360.87 -2.78 (-0.76%) Market Cap: 16.11 Bil Enterprise Value: 13.18 Bil PE Ratio: 15.85 PB Ratio: 2.64 GF Score: 86/100

United Therapeutics Corp at Jefferies Healthcare Conference (Virtual) Transcript

Jun 02, 2020 / 02:30PM GMT
Release Date Price: $123.06 (+2.31%)
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

Hi. This is Eun Yang. I'm a biotech analyst here at Jefferies. This is my pleasure to host a fireside chat with James Edgemond, Chief Financial Officer of United Therapeutics at the Jefferies Virtual Healthcare Conference.

So James, thanks for joining us today.

Questions & Answers

Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

So this is going to be a Q&A. So I'll start with Tyvaso in pulmonary hypertension and interstitial lung disease. UTHR has mentioned previously there are about 30,000 U.S. patients who would be eligible for Tyvaso. How -- can you talk about how you derived that number, 30,000?

James C. Edgemond
United Therapeutics Corporation - CFO & Treasurer

Yes, yes. Eun, thank you. And first of all, I want to thank you and Jefferies really for hosting United Therapeutics today at your virtual health care conference, including this fireside chat.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot